INTRODUCTION AND OBJECTIVES:
We investigated that combination with antimuscarinic agent, solifenacin, or beta-3 adrenoceptor agonist, mirabegron, can increase the therapeutic effect after intravesical onabotuliumtoxinA (Botox) injection for patients with severe overactive bladder (OAB) syndrome.
METHODS: The Institutional Review Board and Ethics Committee of the hospital approved this study. Fifty-eight OAB patients who had severe OAB wet and treated with intravesical 100U Botox injection were consecutively invited to a prospective, randomized, open-label study. The patients were randomly treated with solifenacin 5 mg QD (n[19, group 1), mirabegron 50 mg QD (n[20, group 2), and without medication (n[19, group 3) at 1 month after the Botox injection. All enrolled patients were asked to complete 3-day voiding diary, the Overactive Bladder Symptom Score (OABSS), Urgency Severity Scale (USS) questionnaires, and uroflowmetry at baseline (before Botox injection) and 3-month follow-up. Videourodynamic study was performed before Botox injection. The primary endpoint was the changes of Global Response Assessment (GRA) at 3-month. The secondary endpoint included changes of OABSS, USS and the parameters of voiding diary between baseline and 3-month follow-up.
RESULTS: The mean patients' age was 71.2AE11.0, 68.2AE10.8 and 72.8AE10.2 years old (p [ 0.40) in group 1, 2, and 3, respectively. The baseline data were comparable in three groups. At 3-month, the changes of GRA, OABSS, USS, and nocturia episodes in group 2 were significantly greater than those in group 1 and 3 (Table 1) . Compared with baseline, OABSS and urgency in group 1 were significantly decreased at 3-month. Compared with baseline, OABSS, USS, UUI episodes, nocturia, urgency in group 2 were significantly decreased at 3-month. Maximum flow rate was not decreased but post-void residual urine volume were increased in all groups.
CONCLUSIONS: Adding beta-3 agonist can increase the therapeutic effect in OAB patients after receiving intravesical Botox injection.
